QUALITY. INNOVATION. IMPACT.
NIBI BIOPHARMA PROJECT
Building the Future of Biopharmaceutical Manufacturing in Nigeria
At Nibi Biopharma Limited, we are laying the foundation for a world-class biopharmaceutical industrial complex that will transform Nigeria’s capacity to produce vaccines and essential therapeutics. Through strategic development and advanced infrastructure, the NIBI Project is designed to bridge critical gaps in local biopharmaceutical manufacturing, ensuring a more self-reliant, efficient, and high-quality production system.
Table of Contents
A Vision for Excellence
The Nibi Biopharma Project is a large-scale effort dedicated to positioning Nigeria as a key player in West and Central Africa’s biopharmaceutical industry. Once completed, the project will significantly increase local manufacturing capabilities, reducing the need for imported vaccines and essential medicines while ensuring affordable and accessible medical solutions.
Bridging the Gap in Local Biopharmaceutical Manufacturing
- Reducing reliance on imports by establishing a self-sufficient biopharmaceutical industry in Nigeria.
Our approach integrates cutting-edge scientific research, robust infrastructure, and sustainable production practices to create an ecosystem capable of delivering millions of doses of vaccines and billions of essential therapeutics annually.
State-of-the-Art Facilities and Infrastructure
The Nibi Biopharma Project is being developed with world-class infrastructure that meets the highest global health and regulatory standards. This includes:
📌 Cutting-edge infrastructure for Large-Scale Production
- Multi-line vaccine production capacity: 250 million doses annually.
- Pharmaceuticals manufacturing: 5 billion tablets, 600 million capsules, 300 million ampoules/vials.
Sustainable and Scalable Biopharmaceutical Manufacturing
- Features a 20MW gas-fired power plant for reliable energy supply.
- 150 million litres per year water treatment plant to support production needs.
Each facility is designed to operate at maximum efficiency, utilizing the latest biomanufacturing technology to support high-volume, high-quality production.
Impact on Nigeria’s Healthcare Landscape
The successful implementation of the Nibi Biopharma Project will:
Economic and Industrial Growth
- ✔ Enhance Nigeria’s biopharmaceutical self-sufficiency, reducing dependence on imports.
- ✔ Create over 2,000 permanent jobs, boosting economic growth and industrial development.
- ✔ Improve vaccine and medicine security, ensuring consistent supply for critical health needs.
- ✔ Meet global health standards, positioning Nigeria as a regional hub for biopharmaceutical manufacturing.
Building a Sustainable and Scalable Future
Beyond its immediate impact, the Nibi Biopharma Project is designed for long-term scalability. With a phased implementation approach, it will expand into upstream biologics and pharmaceutical production, including Active Pharmaceutical Ingredients (APIs) and vaccine antigens. This ensures that Nigeria remains at the forefront of biopharmaceutical innovation and supply security.
A Vision for the Future
- Expansion into upstream biologics and Active Pharmaceutical Ingredients (APIs).
- Developing a self-reliant and innovative biopharmaceutical ecosystem for Africa.
A Commitment to Global Health Standards
With unwavering dedication to quality, innovation, and efficiency, Nibi Biopharma Limited is setting a new benchmark for biopharmaceutical manufacturing in Nigeria. Through cutting-edge technology and strategic investment, we are not just building facilities, we are building the future of healthcare in Africa.
Commitment to Global Health and Regulatory Standards
- Facilities designed to meet GMP, WHO, and international regulatory requirements.
- Ensuring affordable, accessible, and high-quality medical solutions.
NIBI BIOPHARMA LIMITED
Let’s Work Together
Be part of a groundbreaking movement in biopharmaceutical manufacturing. Join us in shaping Nigeria’s future in pharmaceutical innovation. Contact us today to explore investment opportunities with Nibi Biopharma Limited.
